Showing results (21-30 of 126) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaDavid S Siegel, Meletios A Dimopoulos, Heinz Ludwig, et al.
Leukemia & Lymphoma|November 6, 2019
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparisonMaria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myelomaHenk Lokhorst, Hermann Einsele, David Vesole, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 20, 2011
How to manage neutropenia in multiple myelomaAntonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 6 from the 11 th International Workshop on Waldenström's Macroglobulinemia on Management of Waldenström's Macroglobulinemia Related AmyloidosisGiampaolo Merlini, Shayna Sarosiek, Giulia Benevolo, et al.
The Journal of Molecular Diagnostics : JMD|July 11, 2006
Application of self-quenched JH consensus primers for real-time quantitative PCR of IGH gene to minimal residual disease evaluation in multiple myelomaJoaquin Martinez-Lopez, Pilar Martinez-Sanchez, Ramon Garcia-Sanz, et al.
British Journal of Haematology|July 20, 2016
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaMaría-Victoria Mateos, Miguel Granell, Albert Oriol, et al.
British Journal of Haematology|February 19, 2020
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysisDolly A Parasrampuria, Jianming He, Liping Zhang, et al.
Blood|March 2, 2019
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Jae Hoon Lee, Philippe Moreau, et al.
Annals of Hematology|October 15, 2016
Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trialsMaria-Victoria Mateos, Albert Oriol, Joaquín Martínez-López, et al.
Pageof 13